公开(公告)号：US20200009176A1

公开(公告)日：2020-01-09

申请号：US16415325

申请日：2019-05-17

Applicant: Epizyme, Inc.

Inventor： Roy M. POLLOCK ,  Scott R. DAIGLE ,  Eric HEDRICK ,  Nigel WATERS ,  Blythe THOMSON

IPC: A61K31/7076 ,  A61P35/02

Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof

公开(公告)号：US20190076455A1

公开(公告)日：2019-03-14

申请号：US15533205

申请日：2015-12-04

Applicant: Epizyme, Inc.

Inventor： Roy M. POLLOCK ,  Scott R. DAIGLE ,  Eric HEDRICK ,  Nigel WATERS ,  Blythe THOMSON

IPC: A61K31/7076 ,  A61P35/02

Abstract: The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.